过氧化值测定实验中饱和碘化钾配制方法的改进

食用植物油脂,在人们日常生活中是极其重要的,它提供人们活动的能量.食用植物油是以脂肪酸甘油酯,包含其他多种组分的混合物,这些组分包括游离脂肪酸、磷酸、植物甾醇、油溶性维生素、色素、氧化产物、微量金属、水份等.……     

白藜芦醇抑制胆囊癌细胞生长与诱导细胞凋亡的实验研究

目的:探讨白藜芦醇(Res)对胆囊癌细胞(GBC)和正常成纤维细胞(3T3)体外增殖的影响,进而观察Res对GBC和3T3细胞凋亡的影响.方法:MTT法测定肿瘤细胞生长抑制率;流式细胞术分析细胞周期,检测细胞凋亡;SABC法检测细胞bcl-2、c-myc、p53蛋白表达.结果:Res呈浓度依赖性抑制GBC细胞的生长与增殖(P＜0.01),抑制率最高可达54%.Res能明显诱导GBC细胞凋亡,凋亡率最高为30.52%;处理组较对照组G1期细胞由34.88%上升至55.47±3.95%,S期细胞减少8.41%～17.54%,呈明显的G0/G1期阻滞现象.GBC细胞的bcl-2、c-myc基因蛋白表达降低,而p53基因蛋白表达增强.结论:Res能通过诱导GBC细胞凋亡而抑制其生长与增殖,但对3T3细胞无此作用.     

奥沙利铂联合卡培他滨治疗体力状况削弱的晚期胃癌临床观察

为了评估奥沙利铂联合卡培他滨治疗体力状况削弱的(KPS≤70)晚期胃癌的毒性和疗效,应用奥沙利铂联合卡培他滨治疗21例晚期胃癌患者。奥沙利铂100mg/m2,静脉滴入,持续3h,d1;卡培他滨1650mg/(m2·d),分2次口服,d1~d14;21d为1个周期。患者每2个周期行CT检查以评估疗效,并监控其毒性。结果:所有患者均可评估毒性,21例中有20例可评估疗效。PR6例(30%),SD8例(40%),PD6例(30%),有效率为30·0%。中位进展时间4·5个月,中位生存时间8·3个月。初步研究结果提示:奥沙利铂联合卡培他滨治疗体力状况削弱(KPS≤70)的晚期胃癌有效,且有良好的耐受性。     

Acupuncture plus Oral Herbal Decoction and Low Back Pain： A Report of 162 Cases

针刺病变部位的腰部夹脊穴,进针深度30 mm,运用平补平泻手法,并配合口服中药桃红四物汤,治疗了162例椎间盘源性腰痛患者.结果显效65例,良好53例,有效37例,无效6例,总有效率96.3%.     

钙化型腰椎间盘突出症手术体会

钙化型腰椎间盘突出是一种特殊类型的腰椎间盘突出症，在病程较长或年龄较大的患者中并不少见。其临床表现及治疗都有一定特殊性，本文介绍作者近年来手术治疗钙化型腰椎间盘突出症的体会。     

正交试验法研制羌活挥发油-β-环糊精包合物

目的:研究羌活挥发油-β-环糊精包合的最佳工艺.方法:采用正交试验法,以包合率和收率为指标,筛选出饱和水溶液法的最佳工艺条件,并用差示扫描量热法和薄层层析法验证包合物的形成.结果:最佳包合条件为:β-环糊精和油的比例4:1,包合温度60℃,搅拌1 h.结论:包合条件易于控制,所得包合物包合率和收率较高.     

康柏西普与雷珠单抗治疗非缺血型视网膜分支静脉阻塞继发黄斑水肿的对比观察

目的对比观察康柏西普与雷珠单抗治疗非缺血型视网膜分支静脉阻塞(BRVO)继发黄斑水肿随访12个月的疗效及注射次数。方法回顾性非随机对照临床研究。收集2016年1月～2017年1月在我院确诊为非缺血型BRVO继发黄斑水肿的患者共38例(38眼),按照治疗药物分为2组,即康柏西普治疗组22例,雷珠单抗组16例,2组均采用按需要治疗(1+PRN)的给药方式。2组患者首次治疗后每月随访1次,共12个月,每次随访检查最佳矫正视力(BCVA)、眼压、检眼镜(眼底镜)、眼底照相、黄斑光学相干层析成像(OCT)。若病情需要则补充荧光素眼底血管造影(FFA)检查。通过观察2组患者BCVA、平均黄斑中心凹厚度(CMT)的变化以及12个月内的总注射次数,比较2种药物的长期疗效。结果随访12个月,2组在治疗后各随访期的BCVA、CMT均比治疗前明显好转(P值均<0. 05); 2组间治疗前和治疗后各随访期的BCVA、CMT水平基本相同,差异无统计学意义(P> 0. 05)。随访12个月,康柏西普组平均注射次数为(1. 64±0. 70)次,雷珠单抗组平均注射次数为(1. 88±0. 67)次,2组之间差异有统计学意义(P <0. 05)。结论康柏西普与雷珠单抗1+PRN方案治疗非缺血型BRVO继发黄斑水肿,观察12个月疗效均确实可靠;康柏西普能有效减少注射次数。     

Maternal serum thrombospondin-1 is significantly altered in cases with established preeclampsia

Purpose: The aim of the study was to investigate whether maternal serum TSP-1 level was associated with PE.

Materials and methods: In our case control study, 84 pregnant women in the third trimester were included. Forty-one of them were healthy and 43 of them were with the diagnosis of PE. The diagnosis was based on the definitions of the National High Blood Pressure Education Program working Group on High Blood Pressure in Pregnancy. Preeclamptic patients were divided into two subgroups as mild and severe. Blood pressure (BP) of pregnant women were obtained in left-side lying position using a mercury sphygmomanometer after at least 10 minutes of rest. Ten milliliters of venous blood was taken from every pregnant women and dispensed into lithium heparin and serum was obtained. Samples were stored at ?80?°C until analyzed. Serum TSP-1 level was measured using enzyme-linked immunosorbent assay (ELISA). All tests were two-tailed and p < .05 was considered to be statistically significant.

Results: TSP-1 level was significantly lower in PE group than in controls (p?=?.003). Platelet counts were similar in two groups (p = .26). TSP-1 levels were significantly lower in severe PE than in mild PE cases. According to the subgroup analysis, TSP-1 level was found significantly lower in severe preeclampsia group compared to control group (p = .015).

Conclusions: In light of the association between endothelial dysfunction and preeclampsia, we claim that lower levels of TSP-1 which is released mostly from endothelial cells seem to reflect disease severity in PE. Our study reveals that maternal serum TSP-1 levels decrease in pregnant women presenting with PE and TSP-1 may be a new biomarker for the detection of PE and even severity of it. Further studies especially prospective ones with greater numbers of cases are needed.